"In a phase 2 trial involving participants with multiple sclerosis, inhibition of CD40L with frexalimab had an effect that generally favored a greater reduction in the number of new gadolinium-enhancing T1-weighted lesions at week 12 as compared with placebo."
#Immunology #autoimmunedisease #autoimmunity #multiplesclerosis

https://www.nejm.org/doi/full/10.1056/NEJMoa2309439?query=featured_home